Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 CAD | +0.62% | +5.88% | -9.50% |
Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.50% | 89.19M | |
+23.30% | 46.4B | |
-1.16% | 41.75B | |
+47.92% | 41.37B | |
-3.52% | 29.71B | |
+10.55% | 26.01B | |
-19.70% | 19.52B | |
+30.93% | 12.43B | |
+0.16% | 12.18B | |
-0.14% | 12.13B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Reports Q1 2022 Net Loss of $0.12 Per Share, Provides Recent Operational Highlights